Severe Acute Respiratory News and Research

RSS

Risk factors for mortality among hospitalized patients with COVID-19

A new study by scientists at biotechnology company Genentech, Inc., and published on the preprint server medRxiv in September 2020 attempts to identify the factors which may shape the risk for death in COVID-19 disease.

27 Sep 2020

CRISPR screening identifies human host pathways that facilitate coronavirus infection

The human coronavirus family consists of 7 known pathogens, for which there are no approved vaccines or specific therapeutic options. Although the seasonal human coronaviruses - OC43, HKU1, 229E, and NL63 – only cause mild respiratory infections, three highly pathogenic coronaviruses that emerged in the last two decades revealed the pandemic potential of this family of viruses.

27 Sep 2020

Young adults now driving force behind the ongoing COVID-19 pandemic says CDC

The Centers for Disease Control and Prevention (CDC) has released a report stating that the ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on the rise among young adults and this rise is preventing the pandemic from abating.

27 Sep 2020

Bacteria-free method for making SARS-CoV-2 infectious clones

Using a circular polymerase chain reaction, researchers have developed a method for making severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant virus, with the ability to introduce mutations. The research by Japanese scientists is published on the preprint server bioRxiv* in September 2020.

27 Sep 2020

Human recombinant soluble ACE2 successfully used in a patient with severe COVID-19

A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.

27 Sep 2020

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

As we improve our understanding of immune responses and correlates of protection against the severe acute respiratory syndrome coronavirus (SARS-CoV-2), two UK researchers emphasize that we will probably utilize different assays to tackle specific questions. Their commentary is published in the prestigious journal Lancet Infectious Diseases.

27 Sep 2020

D614G mutation now the dominant variant in the global COVID-19 pandemic

Now, a new study published on the preprint server medRxiv in September 2020 shows that a significant variant characterized by the D614G mutation has higher infectivity, which may account for its rapid rise to the dominant position in all regions where it has emerged.

25 Sep 2020

Inflammation in the eye after COVID-19

A new study published on the preprint server medRxiv shows the occurrence of ocular pathology in the period of recovery following COVID-19. This throws more light on the occurrence of inflammation in people recovering from COVID-19.

25 Sep 2020

Human-to-cat transmission of SARS-CoV-2 confirmed

Cat-to-cat transmission of SARS-CoV-2 has been experimentally proven, but little is known about the significance of this novel virus as a feline pathogen or its reverse zoonotic potential. The establishment of new animal reservoirs of SARS-CoV-2 could pose serious problems for human health in the future.

24 Sep 2020

A possible inverse relationship between Dengue and COVID-19 in Brazil

Their study titled, “How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in Brazil,” was released pre-peer review on the preprint medRxiv* early this week.

24 Sep 2020

Experimental cancer drug AR-12 inhibits SARS-CoV-2 virus

Nine months into the global pandemic, which has infected more than 32 million people, there is still no approved effective and safe drug or vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Sep 2020

Linoleic acid binds SARS-CoV-2 spike protein

Now, a team of researchers at the Max Planck-Bristol Center for Minimal Biology and Bristol's School of Biochemistry has identified a druggable pocket in the virus's spike protein that can be used to prevent the infection of cells. The study findings, published in the journal Science, are a groundbreaking discovery that will help develop new therapies and drugs to stem the growing pandemic.

24 Sep 2020

School re-openings in US may increase COVID-19 spread unless targeted interventions are in place

In a new study published on the preprint server medRxiv, a team of researchers on behalf of the Imperial College London COVID-19 Response Team used longitudinal and age-specific population mobility and COVID-19 mortality data to model and predict SARS-CoV-2 spread in the US.

24 Sep 2020

Cold plasma inactivates SARS-CoV-2

In one such effort, Zhitong Chen et al., in a recent medRxiv* preprint paper find that by employing an efficient cold atmospheric plasma (CAP) with argon feed gas on different surfaces inactivates the infectious SARS-CoV-2 virus.

24 Sep 2020

Prevalence of SARS-CoV-2 with D614G mutation in a second wave infection in Houston

A recent study reveals that the genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detected in the initial phase of coronavirus disease 2019 (COVID-19) pandemic differ from the variants detected in a massive second wave of infection in Houston, Texas. The study is currently available on the medRxiv preprint server.

24 Sep 2020

Ethnic minority groups disproportionally affected by COVID-19

The study, which assessed the clinical records of more than 17 million adults, also identified inequalities in the risk of needing admission to ICU and the risk of COVID-19-related death.

24 Sep 2020

Tokyo citizens may have developed COVID-19 herd immunity, say researchers

Researchers in Japan and the United States have conducted a study showing that herd immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have developed among the citizens of Tokyo during the summer.

24 Sep 2020

Automated computational protocol identifies potential SARS-CoV-2 MPro inhibitor

As scientists race to discover new and effective antiviral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many novel approaches are being utilized. Now, a new study published on the preprint bioRxiv in September 2020 reports on the discovery of a potentially beneficial enzyme blocker that could inhibit SARS-CoV-2 viral replication.

24 Sep 2020

AI used to define the cytokine storm implicated in fatal COVID-19

A new study published on the preprint server bioRxiv* in September 2020 reports the use of artificial intelligence (AI) to identify an invariant or universal host immune response found in all viral pandemics so far. The association of this response with severe COVID-19 phenotypes indicates a new understanding of the human immune response in viral pandemics.

24 Sep 2020

Research says in SARS-CoV-2 canine infection, transmission unlikely

A new study published on the preprint server bioRxiv* in September 2020 shows that pet dogs have been falling sick and dying of a mysterious respiratory infection, often showing the presence of anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, even though in many cases they do not test positive for COVID-19.

24 Sep 2020